Yookyung Jang

Yookyung Jang

Auto-generated profile, based on publicly available information

Yookyung Jang

Division of Nephrology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Clinical Transplantation and Research
Verified
Journal Article
Open access
PDF file
YJYookyung Jang
Yookyung Jang
TKTai Yeon Koo
Tai Yeon Koo
YCYoung-Eun Choi
Young-Eun Choi
CJCheol Woong Jung
Cheol Woong Jung
YOYoung Ju Oh
Young Ju Oh
MKMyung-Gyu Kim
Myung-Gyu Kim
Yookyung Jang, Tai Yeon Koo, Young-Eun Choi, Cheol Woong Jung, Young Ju Oh, Heungman Jun, Sewon Oh, Sang-Kyung Jo, Myung-Gyu Kim. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0017

11 May 2026 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
TKTai Yeon Koo
Tai Yeon Koo
YCYoung Eun Choi
Young Eun Choi
YJYookyung Jang
Yookyung Jang
SOSewon Oh
Sewon Oh
JYJaeseok Yang
Jaeseok Yang
MKMyung-Gyu Kim
Myung-Gyu Kim
Polypharmacy (PP) is common among kidney transplant recipients (KTRs) due to lifelong immunosuppressive therapy and comorbidity management. However, PP's impact on clinical outcomes remains unclear. In this study, we examine the association between PP and adverse outcomes in KTRs. We analyzed data of 972 KTRs from the Korean Cohort Study for Outcomes in Patients with Kidney Transplantation (KNOW-KT). Excessive PP (ePP) was defined as ≥10 medications at 1-year posttransplantation. Outcomes included all-cause mortality, graft failure, and cardiovascular events. Inverse probability of treatment weighting (IPTW) was used to balance the baseline characteristics. ePP was present in 49% of the KTRs, averaging 9.8 medications. After IPTW, ePP was not significantly associated with allcause mortality or graft failure. However, ePP was significantly associated with an increased risk of cardiovascular events (hazard ratio [HR], 1.80; 95% confidence interval [CI], 1.07-2.96; p = 0.03). This association remained significant after accounting for death as a competing risk (HR, 3.23; 95% CI, 1.40-7.47; p = 0.006). Subgroup analysis showed that the association between ePP and cardiovascular events was more pronounced in male patients and those receiving lipid-lowering agents. Use of immunosuppressive agents was broadly comparable between groups. ePP is highly prevalent among KTRs and is independently associated with an increased risk of cardiovascular events. This association appears to be primarily attributable to the overall PP burden. These findings highlight the importance of regular medication review and individualized pharmacologic strategies to optimize cardiovascular risk management in this population.